mTOR信号通路与滑膜肉瘤研究进展

doi:10.11904/j.issn.1002-3070.2017.05.018

Abstract

Abstract:

The mammalian target of rapamycin(mTOR)is a ser/threonine protein kinase,which belongs to the family of phosphatidylinositol trioxolase-related kinases.By influencing key factors such as AKT,4EBP1 and S6K1,play an important role in the development of tumors.Synovial sarcoma(SS)is a highly malignant soft tissue sarcoma,early surgery and chemotherapy is the mainstream of the current treatment.However,late survival rate is still not ideal.In order to provide A new direction for treatment of synovial sarcoma is provided through the reseach of signaling pathway conduction.In this paper,recent studies on mTOR and synovial sarcoma are reviewed.

Key words: mTOR, Synovial sarcoma, Tumor

CLC Number:

R736.1

LIU Yishu, QU Guofan. Research progress of mTOR signaling pathway and synovial sarcoma[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 477-480.

References

1 Weiss SW,Goldblum JR.Enzinger and weiss's soft tissue tumors[M].5th.St.Louis MO:Mosby Inc,2008:1161-1182.
2 Shi W,Indelicato DJ,Morris CG,et al.Long-term treatment outcomes for patients with synovial sarcoma:a 40-year experience at the University of Florida[J].Am J Clin Oncol,2013,36(1):83-88.
3 Haldar M,Randall RL,Capecchi MR.Synovial sarcoma:from genetics to genetic-based animal modeling[J].Clin Orthop Relat Res,2008,466(9):2156-2167.
4 Sudarsanam S,Johnson DE.Functional consequences of mTOR inhibition[J].Curr Opin Drug Discov Devel,2010,13(1):31-40.
5 Lempiäinen H,Halazonetis TD.Emerging common themes in regulation of PIKKs and PI3Ks[J].EMBO J,2009,28(20):3067-3073.
6 Heitman J,Movva NR,Hall MN.Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast[J].Science,1991,253(5022):905-909.
7 Sabatini DM,Erdjument-Bromage H,Lui M,et al.RAFT1:a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs[J].Cell,1994,78(1):35-43.
8 Laplante M,Sabatini DM.mTOR signaling in growth control and disease[J].Cell,2012,149(2):274-293.
9 Noda T,Ohsumi Y.Tor,a phosphatidylinositol kinase homologue,controls autophagy in yeast[J].J Biol Chem,1998,273(7):3963-3966.
10 Fingar DC,Salama S,Tsou C,et al.Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E[J].Genes Dev,2002,16(12):1472-1487.
11 Chen J,Zheng XF,Brown EJ,et al.Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue[J].Proc Natl Acad Sci U S A,1995,92(11):4947-4951.
12 Friedrichs N,Trautmann M,Endl E,et al.Phosphatidylinositol-3'-kinase/AKT signaling is essential in synovial sarcoma[J].Int J Cancer,2011,129(7):1564-1575.
13 Cassinelli G,Zuco V,Gatti L,et al.Targeting the Akt kinase to modulate survival,invasiveness and drug resistance of cancer cells[J].Curr Med Chem,2013,20(15):1923-1945.
14 Choo AY,Yoon SO,Kim SG,et al.Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation[J].Proc Natl Acad Sci U S A,2008,105(45):17414-17419.
15 Skinner HD,Zheng JZ,Fang J,et al.Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha,HDM2,and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling[J].J Biol Chem,2004,279(44):45643-45651.
16 Guertin DA,Sabatini DM.Defining the role of mTOR in cancer[J].Cancer Cell,2007,12(1):9-22.
17 Huang J,Dibble CC,Matsuzaki M,et al.The TSC1-TSC2 complex is required for proper activation of mTOR complex 2[J].Mol Cell Biol,2008,28(12):4104-4115.
18 Brassesco MS,Cortez MA,Valera ET,et al.Cryptic syt/sxx1 fusion gene in high-grade biphasic synovial sarcoma with unique complex rearrangement and extensive bcl2 overexpression[J].Cancer Genet Cytogenet,2010,196(2):189-193.
19 Peng C,Zhao H,Chen W,et al.Identification of SHCBP1 as a novel downstream target gene of SS18-SSX1 and its functional analysis in progression of synovial sarcoma[J].Oncotarget,2016,7(41):66822-66834.
20 Setsu N,Kohashi K,Fushimi F,et al.Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma[J].Cancer,2013,119(19):3504-3513.
21 Palmerini E,Paioli A,Ferrari S.Emerging therapeutic targets for synovial sarcoma[J].Expert Rev Anticancer Ther,2014,14(7):791-806.
22 Morgan SS,Cranmer LD.Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells[J].BMC Res Notes,2014,7:812.
23 Demetri GD,Chawla SP,Ray-Coquard I,et al.Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy[J].J Clin Oncol,2013,31(19):2485-2492.
24 Phan AT,Dave B.The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors[J].Cancer Med,2016,5(10):2953-2964.
25 Yasui H,Naka N,Imura Y,et al.Tailored therapeutic strategies for synovial sarcoma:receptor tyrosine kinase pathway analyses predict sensitivity to the mTOR inhibitor RAD001[J].Cancer Lett,347(1):114-122.
26 Wagner LM,Fouladi M,Ahmed A,et al.Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma:a report from the Children's Oncology Group[J].Pediatr Blood Cancer,2015,62(3):440-444.
27Slotkin EK,Patwardhan PP,Vasudeva SD,et al.MLN0128,an ATP-competitive mTOR kinase inhibitor,with potent in vitro and in vivo antitumor activity as potential therapy for bone and soft-tissue sarcoma[J].Mol Cancer Ther,2015,14(2):395-406.
28 Cai Y,Xu P,Yang L,et al.HMGB1-mediated autophagy decreases sensitivity to oxymatrine in SW982 human synovial sarcoma cells[J].Sci Rep,2016,6:37845.

[1]	ZHANG Maoxiang,SUN Huixin,SONG Bingbing. Analysis of the incidence and mortality of malignant tumors in Daoli District,Harbin,2008—2012 [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 261-265.
[2]	LIU Yishu,QU Guofan. Progress in long-chain non-coding RNA in osteosarcoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 266-270.
[3]	HOU Yuxue,LI Xiaoli. The research progress of Wnt7a and malignant tumors,and its relationship [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 271-275.
[4]	XU Hui, LI Xi, ZHOU Chunshui. Screening of lung cancer tumor-associated suppressor genes using shRNA library targeting human transcriptome [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 97-102.
[5]	YUAN Guixia, LI Yan, FENG Wanqi, XIA Xiaojuan, LI Xu. Mechanism of tumor suppressor gene DKK2 inhibiting proliferation of nephroblastoma cells in children [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 14-20.
[6]	DING Jiexian, ZHANG Jin, CHEN Yonggang, WANG Xingwen, WANG Shuanke. Progress in Wnt signaling pathway and tumorigenesis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 73-77.
[7]	KAN Jun, ZHOU Daihan, ZHANG Enxin. Research progress in tumor with cardiovascular disease [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 558-561.
[8]	LIU Juan, ZHANG Shutian. Advances in research on the mechanism of cyclin-dependent kinase inhibitor 3(CDKN3)in tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 575-578.
[9]	LI Yue, XU Ke, HAN Zengxiang, SUN Min, FAN Guohua, ZHANG Yong. Advances in the role of tumor-associated macrophage in colon cancer and targeted therapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 450-454.
[10]	WANG Yuan, SUN Yihua. Advance in the role of β-catenin in soft tissue tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 455-459.
[11]	ZHANG Yali, SU Danke. Research progress in gadolinium-based molecular probes for tumor targeting imaging [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 460-463.
[12]	HAN Bangling, WANG Yimin, XUE Yingwei. Research progress of vitamin D in tumors of digestive system [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 471-475.
[13]	SHAO Jiayue,SUN Xiuwei. Effect of allicin combined with 5-FU on apoptosis of colon cancer HT-29 cells and its mechanism [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 289-292.
[14]	HAN Bangling,WANG Yimin,XUE Yingwei. Research progress in the relationship between neutrophils and malignant tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 349-352.
[15]	ZHANG Yiyun,WU Huaxing. Progress of metabolic plasticity in tumor growth and metastasis [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 362-366.

Research progress of mTOR signaling pathway and synovial sarcoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments